Lung Cancer News and Research

Latest Lung Cancer News and Research

Cytokine levels could predict autoimmune reactions to cancer immunotherapy

The development of immunotherapy, which mobilizes the body's own immune system to destroy cancer cells, is one of the greatest advances in cancer treatment, but immunotherapy can cause harm to healthy tissue in some patients.

31 Oct 2018

Scientists find ways to block nitration of amino acids to improve cancer immunotherapy

Immunotherapy -- harnessing T-cells to attack cancer cells in the body -- has given hope to patients who endure round after round of treatment, including chemotherapy, to little effect. For all of its promise, however, immunotherapy still benefits only a minority of patients -- a reality driving research in the field for ways to improve the relatively new approach.

30 Oct 2018

LKSOM and Hunter jointly receive $13.5 million grant from National Cancer Institute

The Lewis Katz School of Medicine at Temple University and Hunter College of the City University of New York have jointly received a five-year, $13.5 million grant from the National Cancer Institute.

30 Oct 2018

Aggressive local therapy for stage IV lung cancer patients improves progression-free survival

Adding radiation therapy or surgery to systemic therapy for stage IV lung cancer patients whose cancer has spread to a limited number of sites can extend overall survival time significantly, according to new results from a multicenter, randomized, controlled phase II study. The findings were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology

30 Oct 2018

Bigger brains linked to greater risk of developing tumors

It may simply be that having a big brain is itself the cause. That's what doctor and PhD candidate Even Hovig Fyllingen at the Norwegian University of Science and Technology (NTNU) has determined with his research colleagues.

29 Oct 2018

Raman microscopy can help detect cancer drug resistance

Biophysicists at Ruhr-Universität Bochum have demonstrated that Raman microscopy can be used to detect the resistance of tumor cells to cancer drugs.

26 Oct 2018

SBRT found to be safe treatment for patients with multiple metastases

The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy could be used safely in oligometastatic patients with multiple metastases.

24 Oct 2018

New medical navigation system receives international innovation award

The team behind a new medical navigation system which makes it easier to take biopsy samples from the lungs recently received an international innovation award during Innovation Expo 2018 in Rotterdam.

23 Oct 2018

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

23 Oct 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.

22 Oct 2018

Study findings could set new standard of care for advanced anal cancer

A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomized clinical trial in this group of patients.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Lung Cancer News and Research

Latest Lung Cancer News and Research

Cytokine levels could predict autoimmune reactions to cancer immunotherapy

Scientists find ways to block nitration of amino acids to improve cancer immunotherapy

LKSOM and Hunter jointly receive $13.5 million grant from National Cancer Institute

Aggressive local therapy for stage IV lung cancer patients improves progression-free survival

Bigger brains linked to greater risk of developing tumors

Raman microscopy can help detect cancer drug resistance

SBRT found to be safe treatment for patients with multiple metastases

New medical navigation system receives international innovation award

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Study: Targeting specific genomic mutation in breast cancer improves survival

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Study findings could set new standard of care for advanced anal cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

The ultimate guide to lung research tools and protocols eBook

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Newsletters you may be interested in